TY  - CONF

T1  - Treatment with amlitelimab (KY1005, SAR445229): A novel nondepleting anti-OX40Ligand (OX40L) mAb reduces IL-13 serum levels in a phase 2a randomized placebo-controlled trial in patients with moderate to severe atopic dermatitis

JO  - JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

PY  - 2022/01/01

AU  - Weidinger S

AU  - Bieber T

AU  - Cork M

ED  - 

VL  - 87

IS  - 3

SP  - AB123

EP  - AB123

Y2  - 2025/10/26

ER  -